Patents by Inventor Bernd W. Mueller
Bernd W. Mueller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140199388Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.Type: ApplicationFiled: March 14, 2014Publication date: July 17, 2014Applicant: Forward Pharma A/SInventors: Henrik NILSSON, Florian Schoenharting, Bernd W. Mueller, Joseph R. Robinson
-
Publication number: 20140199387Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.Type: ApplicationFiled: March 14, 2014Publication date: July 17, 2014Applicant: Forward Pharma A/SInventors: Henrik NILSSON, Florian SCHOENHARTING, Bernd W. MUELLER, Joseph R. ROBINSON
-
Publication number: 20140199390Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.Type: ApplicationFiled: March 14, 2014Publication date: July 17, 2014Applicant: Forward Pharma A/SInventors: Henrik NILSSON, Florian SCHOENHARTING, Bernd W. MUELLER, Joseph R. ROBINSON
-
Publication number: 20140199386Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.Type: ApplicationFiled: March 13, 2014Publication date: July 17, 2014Applicant: Forward Pharma A/SInventors: Henrik NILSSON, Florian SCHOENHARTING, Bernd W. MUELLER, Joseph R. ROBINSON
-
Publication number: 20140200272Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.Type: ApplicationFiled: March 13, 2014Publication date: July 17, 2014Applicant: Forward Pharma A/SInventors: Henrik NILSSON, Florian SCHOENHARTING, Bernd W. MUELLER, Joseph R. ROBINSON
-
Publication number: 20140199392Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.Type: ApplicationFiled: March 14, 2014Publication date: July 17, 2014Applicant: Forward Pharma A/SInventors: Henrik NILSSON, Florian SCHOENHARTING, Bernd W. MUELLER, Joseph R. ROBINSON
-
Publication number: 20140200273Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.Type: ApplicationFiled: March 13, 2014Publication date: July 17, 2014Applicant: FORWARD PHARMA A/SInventors: Henrik NILSSON, Florian SCHOENHARTING, Bernd W. MUELLER, Joseph R. ROBINSON
-
Publication number: 20140199393Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.Type: ApplicationFiled: March 13, 2014Publication date: July 17, 2014Applicant: FORWARD PHARMA A/SInventors: Henrik NILSSON, Florian SCHOENHARTING, Bernd W. MUELLER, Joseph R. ROBINSON
-
Publication number: 20140193495Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.Type: ApplicationFiled: March 13, 2014Publication date: July 10, 2014Applicant: FORWARD PHARMA A/SInventors: Henrik NILSSON, Florian SCHOENHARTING, Bernd W. MUELLER, Joseph R. ROBINSON
-
Publication number: 20140099364Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.Type: ApplicationFiled: October 7, 2005Publication date: April 10, 2014Applicant: Forward Pharma A/SInventors: Henrik NILSSON, Florian SCHOENHARTING, Bernd W. MUELLER, Joseph R. ROBINSON
-
Publication number: 20140093863Abstract: For cooling organs and tissues in transplantation medicine, only ice preparations are used so far which are not soft like a gel and are brought to the necessary degree of comminution by mechanically comminuting frozen, sterile, pyrogen-free isotonic infusion solutions, such as 5% glucose or 0.9% saline, with great effort. The lack of gel-like consistency of the preparations and the expensive production process are very disadvantageous. Therefore, it was necessary to produce a cooling preparation for transplantation medicine, which in a temperature range from ?5° C. to 4° C. is gel-like and soft, transparent and sufficiently mechanically stable and yet remains formable. In accordance with the invention, such preparation can be produced from gelatin solutions in the concentration range of 3-20 wt-%, which are isotonized or adjusted to 280-650 mosmol/kg and are almost pH-neutral, by simple cooling and/or freezing.Type: ApplicationFiled: December 6, 2013Publication date: April 3, 2014Applicant: Fresenius Kabi Deutschland GmbHInventors: Bernd W. Mueller, Klaus Sommermeyer
-
Publication number: 20140037740Abstract: The invention features a delayed release composition wherein the active ingredient consists essentially of about 240 mg of dimethylfumarate and one or more pharmaceutically acceptable excipients.Type: ApplicationFiled: August 1, 2013Publication date: February 6, 2014Applicant: Forward Pharma A/SInventors: Henrik Nilsson, Florian Schönharting, Bernd W. Müller, Joseph R. Robinson
-
Publication number: 20140037720Abstract: The invention relates to a method of treating a subject in need of treatment for multiple sclerosis including orally administering to the subject in need thereof a delayed release pharmaceutical composition using an increasing dose regimen, wherein an initial daily amount of drug administered is increased later to a higher daily amount and the pharmaceutical composition consists essentially of (a) dimethylfumarate and (b) one or more pharmaceutically acceptable excipients.Type: ApplicationFiled: August 1, 2013Publication date: February 6, 2014Applicant: Forward Pharma A/SInventors: Henrik Nilsson, Florian Schönharting, Bernd W. Müller, Joseph R. Robinson
-
Publication number: 20130315993Abstract: The invention features a kit. The kit includes: (i) a first unit dosage form consisting essentially of about 120 mg of dimethylfumarate and one or more pharmaceutically acceptable excipients, wherein the dimethylfumarate is formulated for delayed release; and (ii) a second unit dosage form consisting essentially of about 240 mg of dimethylfumarate and one or more pharmaceutically acceptable excipients, wherein the dimethylfumarate is formulated for delayed release.Type: ApplicationFiled: August 1, 2013Publication date: November 28, 2013Applicant: Forward Pharma A/SInventors: Henrik Nilsson, Florian Schönharting, Bernd W. Müller, Joseph R. Robinson
-
Publication number: 20130316003Abstract: The invention features a method of treating a subject in need of treatment for multiple sclerosis. The method involves orally administering to the subject in need thereof a pharmaceutical composition in unit dosage form consisting essentially of (a) from about 120 mg to about 240 mg of dimethylfumarate formulated for delayed release, and (b) one or more pharmaceutically acceptable excipients, wherein following the orally administering of the unit dosage form monomethylfumarate appears in the plasma of the subject upon hydrolysis of dimethylfumarate and the Cmax of the monomethylfumarate in the plasma of the subject is between about 0.4 and about 2 mg/L, and wherein about 480 mg of dimethylfumarate per day is orally administered to the subject.Type: ApplicationFiled: August 1, 2013Publication date: November 28, 2013Applicant: Forward Pharma A/SInventors: Henrik NILSSON, Florian SCHÖNHARTING, Bernd W. MÜLLER, Joseph R. ROBINSON
-
Publication number: 20110281810Abstract: The present invention relates to the use of a solubilizer for enhancing the solubility of an active pharmaceutical ingredient in water. The present invention further relates to a composition comprising a solubilizer and at least one active pharmaceutical ingredient. In both cases the solubilizer is an alkoxylated monoalcohol or a mixture of alkoxylated monoalcohols, where the alkoxylated monoalcohol or, if a mixture of alkoxylated monoalcohols is present, at least one alkoxylated monoalcohol in the mixture comprises at least one oxypropylene unit.Type: ApplicationFiled: April 13, 2011Publication date: November 17, 2011Applicant: Cognis IP Management GmbHInventors: Kirsten Petersen, Bernd W. Müller, Thomas Rosen
-
Publication number: 20110217283Abstract: The invention relates to a method for the production of a medicament containing a polypeptide comprising at least one recombinant carbohydrate-binding polypeptide, or a functional fragment or derivative of said carbohydrate-binding polypeptide in a form stable for storage. The polypeptide mentioned comprises polypeptides or functional derivatives thereof, which are fused with cytotoxically effective peptides to give fusion proteins, or which are linked to another polypeptide having a cytotoxic activity. Moreover, the invention describes further formulating of the disclosed medicaments to medicaments with different pharmaceutical forms.Type: ApplicationFiled: May 6, 2011Publication date: September 8, 2011Inventors: Oliver Gloger, Bernd W. Müller, Klaus Witthohn
-
Publication number: 20110159102Abstract: The disclosure relates to a process for continuously producing spherical powder agglomerates, in which morphologically irregular starting agglomerates of micronized pulverulent particles are rounded off continuously by application to a surface induced to vibrate.Type: ApplicationFiled: October 13, 2008Publication date: June 30, 2011Applicant: Pharmatech GmbHInventors: Thorsten Hartmann, Bernd W. Müller, Hartwig Steckel
-
Publication number: 20100297599Abstract: For cooling organs and tissues in transplantation medicine, only ice preparations are used so far which are not soft like a gel and are brought to the necessary degree of comminution by mechanically comminuting frozen, sterile, pyrogen-free isotonic infusion solutions, such as 5% glucose or 0.9% saline, with great effort. The lack of gel-like consistency of the preparations and the expensive production process are very disadvantageous. Therefore, it was necessary to produce a cooling preparation for transplantation medicine, which in a temperature range from ?5° C. to 4° C. is gel-like and soft, transparent and sufficiently mechanically stable and yet remains formable. In accordance with the invention, such preparation can be produced from gelatin solutions in the concentration range of 3-20 wt-%, which are isotonized or adjusted to 280-650 mosmol/kg and are almost pH-neutral, by simple cooling and/or freezing.Type: ApplicationFiled: September 17, 2008Publication date: November 25, 2010Inventors: Bernd W. Mueller, Klaus Sommermeyer
-
Publication number: 20100190706Abstract: The present invention relates to shelf stable non-aqueous pharmaceutical compositions, and to the use thereof in methods of treating diabetes and hyperglycaemia, comprising insulinotropic peptide and semi-polar protic organic solvent.Type: ApplicationFiled: May 30, 2008Publication date: July 29, 2010Applicant: NOVO NORDISK A/SInventors: Simon Bjerregaard Jensen, Svend Havelund, Anders Föger, Bernd W. Müller